Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11775
Peer-review started: May 12, 2022
First decision: August 4, 2022
Revised: August 9, 2022
Accepted: October 17, 2022
Article in press: October 17, 2022
Published online: November 16, 2022
Processing time: 180 Days and 1.3 Hours
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal surface malignancy can effectively control the disease, however it is also associated with adverse effects which may affect quality of life (QoL).
Investigations of perioperative QoL and symptom severity after CRS/HIPEC are limited. The impact on QoL of this treatment has also gradually become more important due to socio-economic considerations.
The main objective of this study was to investigate early perioperative QoL after CRS/HIPEC, which has not previously been discussed in Taiwan.
We performed an observational, prospective, single-center cohort study and enrolled patients who received CRS/HIPEC at Chang-Gung Memorial Hospital in Chiayi between September 1, 2018 and February 28, 2021. We assessed QoL using the Taiwanese version of the MD Anderson Symptom Inventory (MDASI-T) and European Organization Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). The participants completed the questionnaires before CRS/ HIPEC (S1), at the first outpatient follow-up (S2), and 3 mo after CRS/HIPEC (S3).
Most patients had a significant decline in physical and role function scores at S2, but they returned to the preoperative status at S3. The most serious symptoms after surgery were fatigue and pain, and pain returned to the preoperative status 3 mo after surgery. There was no significant decline in global health status after surgery. Both items in the MDASI-T were significantly negatively correlated with the EORTC QLQ-C30 results. The important determinants of QoL were age ≥ 55 years old in emotional functioning at S2 (β = -0.40, P < 0.05), and performance status in preoperative physical functioning (β = 21.49, P < 0.05) and role functioning at S3 (β = 29.63, P < 0.05).
QoL and symptom severity improved or returned to baseline in most categories within 3 mo after CRS/HIPEC. Understanding the clinical course may relieve the patients’ anxiety over their disease. Our findings may help physicians with preoperative consultation and perioperative care.
As this study had a relatively small sample size and was prospective in design, larger studies with multiple centers and fewer influences factors are warranted to explore the QoL after HIPEC.